Premium
EFFECT OF NEUTRAL ENDOPEPTIDASE INHIBITOR IN RATS WITH CONGESTIVE HEART FAILURE
Author(s) -
Murohara Yoshiharu,
Johnston Colin I.
Publication year - 1992
Publication title -
clinical and experimental pharmacology and physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.752
H-Index - 103
eISSN - 1440-1681
pISSN - 0305-1870
DOI - 10.1111/j.1440-1681.1992.tb00477.x
Subject(s) - medicine , heart failure , neprilysin , natriuresis , atrial natriuretic peptide , diuresis , cardiology , endocrinology , hemodynamics , cardiac function curve , natriuretic peptide , cardiac index , blood pressure , vascular resistance , cardiac output , renal function , chemistry , biochemistry , enzyme
SUMMARY 1. The acute hormonal, renal and haemodynamic effects of SCH 39370, a new neutral endopeptidase (NEP) inhibitor, were evaluated in rats with congestive heart failure (CHF) produced by coronary ligation. 2. Left ventricular systolic pressure and left ventricular end diastolic pressure were significantly decreased by SCH 39370 treatment. 3. SCH 39370 improved cardiac function by increasing cardiac index and decreasing total peripheral resistance. 4. SCH 39370 induced a transient but significant diuresis and natriuresis. 5. These effects were associated with significant increases in urinary atrial natriuretic peptide (ANP) and cyclic GMP excretion, but not with an increase in plasma ANP levels. 6. The results suggest that NEP inhibition may be a new therapeutic method for treating CHF possibly by potentiating the biological activities of endogenous ANP.